Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics Inc (NQ: STOK )

12.05 +0.62 (+5.42%)
Streaming Delayed Price Updated: 2:53 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 94 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 540 companies set new 52-week lows. 
Via Benzinga
Recap: Stoke Therapeutics Q1 Earnings
Stoke Therapeutics (NASDAQ:STOK) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Stoke Therapeutics reported... 
Via Benzinga
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows. 
Via Benzinga
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 9.6% to $23.84 during Wednesday's after-market session. The market value of their outstanding shares is at $312.8 million. As per the... 
Via Benzinga
Recap: Stoke Therapeutics Q4 Earnings
Stoke Therapeutics (NASDAQ:STOK) reported its Q4 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) and Stoke Therapeutics Inc (NASDAQ: STOK) will team up on the treatments in rare genetic neurodevelopmental diseases of... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
From Acadia Pharmaceuticals Inc.
Via Business Wire
Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Touts Early Signs Of Efficacy For Antisense Drug In Dravet Syndrome
Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American... 
Via Benzinga
Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 3, 2021
Upgrades Cowen & Co. upgraded the previous rating for Marvell Technology Inc (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare... 
Via Benzinga
Exposures Product Safety
40 Stocks Moving In Monday's Mid-Day Session
Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE: 
Via Benzinga
Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
From Stoke Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.